---

Chronic Bronchitis: From Basics to Clinical

---

1. Definition

• Robbins & Kumar Basic Pathology
• Goldman-Cecil Medicine

---

2. Epidemiology & Risk Factors

• Predominantly a disease of smokers - ~90% of affected patients have a significant smoking history, often 40+ pack-years
• Affects adults, typically presenting in the 6th decade or later
• Other exposures: biomass fuel combustion (poorly ventilated spaces), occupational dusts (grain, cotton, silica mines), sulfur dioxide, nitrogen dioxide air pollutants
• In the US, COPD (the umbrella that includes CB with obstruction) costs approximately $50 billion annually in direct and indirect costs
• Globally, COPD causes ~3.2 million deaths/year (3rd leading cause of death worldwide)
• Up to 30% of the community smokes, but chronic bronchitis is only reported in ~5% of patients seeking medical care for cough
• Goldman-Cecil Medicine
• Murray & Nadel's Textbook of Respiratory Medicine

---

3. Pathogenesis

3a. Mucus Hypersecretion

• Cigarette smoke and air pollutants trigger hypertrophy of mucous glands in the trachea and large bronchi
• Goblet cell hyperplasia in small airways (bronchi and bronchioles)
• The enlargement of submucosal glands and increase in goblet cells may represent a protective/adaptive response that becomes maladaptive
• Inflammatory mediators, particularly IL-13 from T cells and histamine, drive mucin expression
• Neutrophil elastase production is also increased by tobacco smoke exposure

3b. Acquired CFTR Dysfunction

• Smoking leads to acquired CFTR dysfunction, causing secretion of abnormal, dehydrated mucus - exacerbating severity (this is a key insight from Robbins Cotran, linking CB mechanistically to CF-like pathology)

3c. Inflammation

• Cellular damage from inhaled irritants elicits neutrophils, macrophages, and lymphocytes
• Note: eosinophils are NOT prominently seen (distinguishes from asthma)
• Long-standing airway inflammation + fibrosis in small airways leads to chronic obstruction

3d. Role of Infection

• Infection does not initiate chronic bronchitis
• However, it is critical in maintaining inflammation and precipitating acute exacerbations
• Common pathogens: Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae

3e. Airflow Obstruction Mechanism

• Large airway changes (mucous gland hypertrophy) cause the sputum production
• Airflow obstruction, however, results from small airway disease (chronic bronchiolitis): mucous plugging + inflammation + bronchiolar wall fibrosis in airways <2-3 mm diameter
• Ciliary dysfunction from smoke prevents mucociliary clearance, perpetuating the cycle
• Robbins & Kumar Basic Pathology
• Robbins, Cotran & Kumar Pathologic Basis of Disease

---

4. Morphology / Pathology

Gross Findings

• Mucosal lining of large airways is hyperemic, edematous, swollen
• Covered by a layer of mucinous or mucopurulent secretions
• Smaller bronchi and bronchioles may be filled with secretion casts

Microscopic Findings

• Robbins & Kumar Basic Pathology
• Robbins, Cotran & Kumar Pathologic Basis of Disease

---

5. Clinical Features

Classic Presentation: "Blue Bloater"

Additional Clinical Findings

• Hemoptysis may occur, especially during exacerbations - always warrants evaluation for lung cancer
• Clubbing is NOT a feature of CB/COPD - if present, evaluate for lung cancer or pulmonary fibrosis
• Wheezing may be present (asthmatic bronchitis variant with airway hyperresponsiveness)
• Morning cough worsening, productive throughout the day
• Symptoms are worst in winter months
• Exacerbations are triggered by viral/bacterial URTIs, environmental pollutants
• Advanced disease: hypoxemia (cyanosis), hypercapnia (elevated serum bicarbonate as clue on labs), cor pulmonale, pulmonary hypertension

Complications

• Pulmonary hypertension → cor pulmonale → right heart failure
• Respiratory failure (acute on chronic)
• Recurrent pneumonias
• Obstructive sleep apnea (10-30% of COPD patients)
• Atrial fibrillation and other arrhythmias
• Depression (frequent comorbidity)
• Polycythemia (secondary to chronic hypoxemia)
• Robbins, Cotran & Kumar Pathologic Basis of Disease
• Goldman-Cecil Medicine

---

6. Investigations

Spirometry (Most Important)

• FEV1/FVC < 0.7 (post-bronchodilator) defines airflow obstruction/COPD
• FEV1 is reduced; FVC is normal or near-normal early on
• GOLD staging classifies severity by % predicted FEV1

Arterial Blood Gases

• Type 2 respiratory failure: hypoxemia + hypercapnia (PaO2 ↓, PaCO2 ↑)
• Compensatory metabolic alkalosis: elevated serum HCO3 is a clue that hypercarbia is chronic
• ABG required to confirm hypercarbia (pulse oximetry only shows SpO2)

Chest X-Ray

• Prominent bronchial markings ("dirty chest")
• Enlarged heart if cor pulmonale present
• Less useful for pure CB (no hyperinflation unlike emphysema)

HRCT Chest

• Airway wall thickening, mucus plugging
• Distinguishes CB from emphysema, bronchiectasis
• Bullae suggest emphysematous component

Sputum

• Mucoid (stable) or mucopurulent (exacerbation)
• Culture during exacerbations to guide antibiotic choice

ECG/Echo

• In advanced disease: right heart strain, pulmonary hypertension assessment
• Echocardiography may be limited by hyperinflation (retrosternal air)

---

7. Differential Diagnosis

---

8. Treatment

8a. Non-Pharmacological (Foundational)

• Smoking cessation - most effective intervention; cough typically reduces within 4-5 weeks of quitting
• Pulmonary rehabilitation
• Avoidance of occupational and environmental triggers
• Influenza and pneumococcal vaccinations
• Chest physiotherapy for secretion clearance

8b. Bronchodilators (Mainstay)

• Short-acting beta-2 agonists (SABA) - e.g., salbutamol/albuterol: relieves acute bronchospasm
• Short-acting muscarinic antagonists (SAMA) - e.g., ipratropium: reduces secretions + bronchodilation
• Long-acting beta-2 agonists (LABA) - e.g., salmeterol, formoterol
• Long-acting muscarinic antagonists (LAMA) - e.g., tiotropium: first-line maintenance for stable COPD

8c. Inhaled Corticosteroids (ICS)

• Added for patients with frequent exacerbations or eosinophil count >100-300 cells/µL
• Combined ICS + LABA suppresses airway inflammation
• Triple therapy: ICS + LABA + LAMA for severe cases

8d. Roflumilast (PDE4 inhibitor - oral)

• Specifically indicated for severe COPD with chronic bronchitis and frequent exacerbations
• GOLD guidelines recommend as add-on:
  • In patients with exacerbations despite LABA/LAMA, if eosinophils <100 cells/µL
  • In patients with CB + FEV1 <50% + ≥1 hospitalization on triple therapy
• Small but significant reduction in exacerbation rate
• Side effects: GI (diarrhea, nausea, weight loss), neuropsychiatric (depression, anxiety, suicidality) - monitor closely
• Contraindicated in Child-Pugh B/C liver disease

8e. Mucoactive Agents

• Guaifenesin (expectorant): increases airway water to facilitate mucus expulsion
• N-acetylcysteine (mucolytic): breaks disulfide bonds in mucin, reduces viscosity
• Hypertonic saline nebulization: osmotically draws water into airway lumen
• Beta-2 agonists (mukokinetic): enhance ciliary activity
• Anticholinergics (mucoregulators): reduce mucus secretion

8f. Long-Term Oxygen Therapy (LTOT)

• Indicated if resting PaO2 ≤55 mmHg or SpO2 ≤88% (or PaO2 56-59 with cor pulmonale/polycythemia)

• 15 hours/day shown to improve survival in hypoxic cor pulmonale complicating CB (landmark MRC Trial, 1981)

8g. Management of Exacerbations

• Antibiotics (amoxicillin, doxycycline, or macrolide for outpatient; broader coverage for inpatients)
• Short-course systemic corticosteroids (5-7 days prednisolone)
• Intensified bronchodilator therapy (nebulized SABA ± SAMA)
• Controlled oxygen therapy (target SpO2 88-92% to avoid hypercapnic drive suppression)
• Non-invasive ventilation (NIV/BiPAP) for acute hypercapnic respiratory failure (pH <7.35)

8h. Surgical / Interventional

• Lung volume reduction surgery (selected emphysema-dominant patients)
• Lung transplantation (end-stage, selected patients)
• Murray & Nadel's Textbook of Respiratory Medicine
• Goldman-Cecil Medicine
• Fishman's Pulmonary Diseases and Disorders
• Goodman & Gilman's Pharmacological Basis of Therapeutics

---

9. Prognosis & Natural History

• In a smoker, the presence of chronic bronchitis is predictive of progressive irreversible airflow obstruction leading to COPD
• Some patients retain a persistent productive cough without ever developing airflow obstruction - these have a better prognosis
• Patients with a dominant bronchitic component have more frequent exacerbations, more rapid disease progression, and poorer outcomes than those with emphysema alone
• Progressive disease leads to: pulmonary hypertension → cor pulmonale → right heart failure
• Death can result from:
  • Acute respiratory failure (infection superimposed on COPD)
  • Right heart failure (cor pulmonale)
  • Pneumothorax (from emphysematous blebs)
  • Lung cancer (due to shared risk factors + squamous metaplasia progression)

---

Summary at a Glance

---